{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T04:43:50Z","timestamp":1693111430569},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1007\/s11940-000-0052-8","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T18:17:36Z","timestamp":1180981056000},"page":"355-360","source":"Crossref","is-referenced-by-count":6,"title":["Cysticercosis"],"prefix":"10.1007","volume":"2","author":[{"given":"James F.","family":"Bale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/clinids\/24.2.101","volume":"24","author":"AC White","year":"1997","unstructured":"White AC: Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997, 24:101\u2013105. A well-written, extremely comprehensive review that summarizes the fascinating immunopathogenesis of neurocysticercosis and the current controversies regarding the role of antihelminthic therapy in the treatment of the disorder. If there is time to read but one article regarding neurocysticercosis, this should be the one.","journal-title":"Clin Infect Dis"},{"key":"52_CR2","first-page":"545","volume-title":"Central Nervous System Diseases and Therapy","author":"J Sotelo","year":"1997","unstructured":"Sotelo J: Neurocysticercosis. In Central Nervous System Diseases and Therapy. Edited by Roos K. New York: Marcel Dekker, Inc; 1997:545\u2013572. A thorough review of the condition by a very knowledgeable expert in the diagnosis and treatment of neurocysticercosis."},{"key":"52_CR3","first-page":"1","volume":"41","author":"LA Lettau","year":"1992","unstructured":"Lettau LA, Gardner S, Tennis J, et al.: Locally acquired neurocysticercosis\u2014North Carolina, Massachusetts, and South Carolina, 1989\u20131991. MMWR Morb Mortal Wkly Rep 1992, 41:1\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1542\/peds.82.1.24","volume":"82","author":"WG Mitchell","year":"1988","unstructured":"Mitchell WG, Crawford TO: Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. Pediatrics 1988, 82:76\u201382.","journal-title":"Pediatrics"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archneur.1988.00520310087022","volume":"45","author":"D Scharf","year":"1988","unstructured":"Scharf D: Neurocysticercosis: two hundred and thirty eight cases from a California hospital. Arch Neurol 1988, 45:777\u2013780.","journal-title":"Arch Neurol"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archinte.1985.00360030074016","volume":"145","author":"J Sotelo","year":"1985","unstructured":"Sotelo J, Guerrero V, Rubio F: Neurocysticercosis: a new classification based on active and inactive forms. Arch Intern Med 1985, 145:442\u2013445.","journal-title":"Arch Intern Med"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1212\/WNL.42.10.2055-b","volume":"42","author":"OH Brutto Del","year":"1992","unstructured":"Del Brutto OH, Santibanez R, Noboa CA, et al.: Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992, 42:389\u2013392.","journal-title":"Neurology"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1528-1157.1998.tb01287.x","volume":"39","author":"A Carpio","year":"1998","unstructured":"Carpio A, Escobar A, Hauser WA: Cysticercosis and epilepsy: a critical review. Epilepsia 1998, 39:1025\u20131040. A well-written review that emphasizes the importance of neurocysticercosis as a major cause of epilepsy in regions endemic for T. solium. The article contains an excellent summary of the epidemiology of neurocysticercosis and epilepsy and discusses the concept of transitional forms of neurocysticercosis.","journal-title":"Epilepsia"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3171\/jns.1987.66.5.0686","volume":"66","author":"J Sotelo","year":"1987","unstructured":"Sotelo J, Marin C: Hydrocephalus secondary to cysticercotic arachnoiditis. J Neurosurg 1987, 66:686\u2013689.","journal-title":"J Neurosurg"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00341940","volume":"30","author":"J Lotz","year":"1988","unstructured":"Lotz J, Hewlett R, Alheit B, Bowen R: Neurocysticercosis: correlative pathology and MR imaging. Neuroradiology 1988, 30:35\u201341.","journal-title":"Neuroradiology"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/infdis\/164.5.1007","volume":"164","author":"M Wilson","year":"1991","unstructured":"Wilson M, Bryan RT, Fried JA, et al.: Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991, 164:1007\u20131009.","journal-title":"J Infect Dis"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00006454-199306000-00001","volume":"12","author":"JW St.Geme","year":"1993","unstructured":"St.Geme JW, Maldonado YA, Enzmann D, et al.: Consensus: diagnosis and management of neurocysticercosis in children. Pediatr Infect Dis J 1993, 12:455\u2013461. A summary of expert opinions regarding the treatment of neurocysticercosis presented in a point-counterpoint fashion.","journal-title":"Pediatr Infect Dis J"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archneur.1995.00540250109020","volume":"52","author":"LD Kramer","year":"1995","unstructured":"Kramer LD: Medical treatment of cysticercosis: ineffective. Arch Neurol 1995, 52:101\u2013102. Together with Del Brutto\u2019s article on pages 102 to 104 of the same issue, which champions the effectiveness of medical treatment, this is another concise point-counterpoint debate regarding the benefits of specific antiparasitic therapy in neurocysticercosis.","journal-title":"Arch Neurol"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/clinids\/17.4.730","volume":"17","author":"OH Brutto Del","year":"1993","unstructured":"Del Brutto OH, Sotelo J, Roman GC: Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis 1993, 17:30\u201335. Although somewhat older, this article summarizes well the approach to managing neurocysticercosis based on the location of infection.","journal-title":"Clin Infect Dis"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3201\/eid0303.970324","volume":"3","author":"C Evans","year":"1997","unstructured":"Evans C, Garcia HH, Gilman RH, Friedland JS: Controversies in the management of cysticercosis. Emerg Infect Dis 1997, 3:403\u2013405.","journal-title":"Emerg Infect Dis"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM199209033271004","volume":"327","author":"PM Schantz","year":"1992","unstructured":"Schantz PM, Moore AC, Munoz JL, et al.: Neurocysticercosis in an orthodox Jewish community in New York City. N Engl J Med 1992, 327:692\u2013695.","journal-title":"N Engl J Med"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1227\/00006123-199102000-00009","volume":"28","author":"WT Couldwell","year":"1991","unstructured":"Couldwell WT, Zee CS, Apuzzo MLJ: Definition of the role of contemporary surgical management in cisternal and parenchymal cysticercosis cerebri. Neurosurgery 1991, 28:231\u2013237.","journal-title":"Neurosurgery"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/41.2.145","volume":"41","author":"P Venkatesan","year":"1998","unstructured":"Venkatesan P: Albendazole. J Antimicrob Chemother 1998, 41:145\u2013147. A review of the value of albendazole in the treatment of various parasitic diseases.","journal-title":"J Antimicrob Chemother"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1212\/WNL.48.5.1421","volume":"48","author":"HH Garcia","year":"1997","unstructured":"Garcia HH, Gilman RH, Horton J, et al.: Albendazole therapy for neurocysticercosis: a prospective doubleblind trial comparing 7 versus 14 days of treatment. Neurology 1997, 48:1421\u20131427. A recent study of the use of albendazole in patients with active neurocysticercosis, using CT appearance of lesions as a major therapeutic outcome measure. Remarkably, only 38% had \u201ccomplete cure,\u201d defined as radiographic disappearance of all active lesions at 3 months. Three of 10 patients who had \u201ccure\u201d at 3 months had active lesions detected at the 1-year follow-up.","journal-title":"Neurology"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006454-199808000-00007","volume":"17","author":"AK Baranwal","year":"1998","unstructured":"Baranwal AK, Singhi PD, Khandelwal N, et al.: Albendazole therapy in children with focal seizures and single, small enhancing computerized tomographic lesions: a randomized, placebo-controlled, doubleblind trial. Pediatr Infect Dis J 1998, 17:696\u2013700. This prospective study represents one of the few that have included a placebo control arm. All children received dexamethasone during the first 5 days of therapy. Outcome measures included the CT appearance of lesions and the rates of seizure recurrence. Children who received albendazole had higher rates of lesion resolution (64.5% vs 37.5%; P<0.05) at 3 months and lower rates of recurrent seizures (31.3% vs 12.9%) after 4 weeks, suggesting that albendazole therapy is warranted. Remarkably, nearly 40% of the untreated patients had resolution of lesions at 3 months. One wonders what outcome would be at 1 year of follow-up.","journal-title":"Pediatr Infect Dis J"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ajhp\/55.6.598","volume":"55","author":"SS Mehta","year":"1998","unstructured":"Mehta SS, Hatfield S, Jessen L, Vogel D: Albendazole versus praziquantel for neurocysticercosis. Am J Health Syst Pharm 1998, 55:598\u2013600. An excellent, concise summary of the two currently available drugs used in the treatment of neurocysticercosis. Although efficacy seems nearly equivalent (or slightly in favor of albendazole), the lower cost and cerebrospinal fluid penetration indicate that albendazole should be the drug of choice.","journal-title":"Am J Health Syst Pharm"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198404193101601","volume":"316","author":"J Sotelo","year":"1984","unstructured":"Sotelo J, Escobedo F, Rodriguez-Carbajal J, et al.: Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 1984, 316:1001\u20131007. One of the first studies to suggest benefit from specific antiparasitic therapy. The study included small numbers, however, did not randomize, and used CT appearance of the lesions as the primary outcome measure.","journal-title":"N Engl J Med"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM199209033271005","volume":"327","author":"V Vazquez","year":"1992","unstructured":"Vazquez V, Sotelo J: The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 1992, 327:696\u2013701. A subsequent study from the same institution concluded that praziquantel therapy reduced the frequency of seizures 3 years after treatment. The retrospective study design detracts from the power of the observation, however.","journal-title":"N Engl J Med"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.52.5.1079","volume":"52","author":"OH Brutto Del","year":"1999","unstructured":"Del Brutto OH, Campos X, Sanchez J, Mosquera A: Single day praziquantel versus 1 week albendazole for neurocysticercosis. Neurology 1999, 52:1079\u20131081. A small-scale study, using CT appearance as the outcome measure, that shows no differences between praziquantel and albendazole in these regimens.","journal-title":"Neurology"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archneur.1988.00520290064015","volume":"45","author":"J Sotelo","year":"1988","unstructured":"Sotelo J, Escobedo R, Penagos P: Albendazole vs. praziquantel for therapy for neurocysticercosis. Arch Neurol 1988, 45:532\u2013533. Another small study that shows no differences between praziquantel and albendazole.","journal-title":"Arch Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0052-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0052-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:02:40Z","timestamp":1683867760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0052-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}